Retrospective and Randomized Analysis of Influence and Correlation of Clinical and Molecular Prognostic Factors in a Mono-Operative Series of 122 Patients with Glioblastoma Treated with STR or GTR
Open Access
- 9 February 2020
- journal article
- research article
- Published by MDPI AG in Brain Sciences
- Vol. 10 (2), 91
- https://doi.org/10.3390/brainsci10020091
Abstract
Glioblastoma is a solid, infiltrating, and the most frequent highly malignant primary brain tumor. Our aim was to find the correlation between sex, age, preoperative Karnofsky performance status (KPS), presenting with seizures, and extent of resection (EOR) with overall survival (OS), progression-free survival (PFS), and postoperative KPS, along with the prognostic value of IDH1, MGMT, ATRX, EGFR, and TP53 genes mutations and of Ki67 through the analysis of a single-operator series in order to avoid the biases of a multi-operator series, such as the lack of homogeneity in surgical and adjuvant nonsurgical treatments. A randomized retrospective analysis of 122 patients treated by a single first operator at Sapienza University of Rome was carried out. After surgery, patients followed standard Stupp protocol treatment. Exclusion criteria were: (1) patients with primary brainstem and spinal cord gliomas and (2) patients who underwent partial resections (resection < 90%) or a biopsy exclusively for diagnostic purposes. Statistical analysis with a simultaneous regression model was carried out through the use of SPSS 25® (IBM). Results showed statistically significant survival increase in four groups: (1) patients treated with gross total resection (GTR) (p < 0.030); (2) patients with mutation of IDH1 (p < 0.0161); (3) patients with methylated MGMT promoter (p < 0.005); (4) patients without EGFR amplification or EGFRvIII mutation (p < 0.035). Higher but not statistically significant survival rates were also observed in: patients <75 years, patients presenting with seizures at diagnosis, patients affected by lesions in noneloquent areas, as well as in patients with ATRX gene mutation and Ki-67 < 10%.This publication has 32 references indexed in Scilit:
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011Neuro-Oncology, 2014
- Residual tumor volume and patient survival following reoperation for recurrent glioblastomaJournal of Neurosurgery, 2014
- Seizure Prognosis in Brain Tumors: New Insights and Evidence-Based ManagementThe Oncologist, 2014
- New Editorial Team for Neuro-OncologyNeuro-Oncology, 2013
- Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to TemozolomideAnnals of Surgical Oncology, 2013
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical TrialJournal of Clinical Oncology, 2013
- Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiformeNeuro-Oncology, 2013
- Impact of extent of resection for recurrent glioblastoma on overall survivalJournal of Neurosurgery, 2012
- Genetic Pathways to Primary and Secondary GlioblastomaThe American Journal of Pathology, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005